PDX Programs for Clinical Advancement of Oncology Agents, presented by Neal Goodwin, PhD, Vice President of Research Development
Find out how the Champions TumorGraft platform is being used for conducting high-throughput translational medicine trials across a multitude of patient tumor models, including acute myelogenous leukemia (AML). Additionally, hear how co-clinical and matched PDX-directed trials are being implemented through several industry and academic partnerships.
- Introduction to the PDX algorithm
- Overview of Champions Oncology PDX tumor bank
- Overview of Champions Oncology co-clinical program
- AML modeling
- CD34+ HSC-derived humanized PDX models for immuno-therapy testing